Early Solutions, UCB Biopharma UK, Slough, UK.
PV Supply and Technology Solutions, UCB Biopharma UK, Slough, UK.
MAbs. 2023 Jan-Dec;15(1):2160229. doi: 10.1080/19420862.2022.2160229.
TrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable 'reach' properties. We demonstrate the format's broad functionality by co-targeting of soluble and cell surface antigens. The benefit of monovalent target binding is illustrated by the lack of formation of large immune complexes when co-targeting multivalent antigens. TrYbes® are manufactured using standard mammalian cell culture and protein A affinity capture processes. TrYbes® have been formulated at high concentrations and have favorable drug-like properties, including stability, solubility, and low viscosity. The unique functionality and inherent developability of the TrYbe® makes it a promising multi-specific antibody fragment format for antibody therapy.
TrYbe® 是一种无 Fc 的治疗性抗体形式,能够同时结合多达三个靶点,通过与白蛋白结合而具有长半衰期。小角度 X 射线散射显示,该结构具有构象灵活性和良好的“可达性”特性。我们通过共靶向可溶性和细胞表面抗原来证明该结构的广泛功能。当共靶向多价抗原时,单价靶标结合的优势体现在不会形成大的免疫复合物。TrYbe® 使用标准的哺乳动物细胞培养和蛋白 A 亲和捕获工艺制造。TrYbe® 已在高浓度下进行配制,并具有良好的药物样特性,包括稳定性、溶解性和低粘度。TrYbe® 的独特功能和固有可开发性使其成为一种有前途的多特异性抗体片段形式,可用于抗体治疗。